AllSci News
Lee's Pharm picks up 1cBio's preclinical PARP1 inhibitor for China and SE Asia
Lee's Pharmaceutical Holdings (HKEX: 00950) has licensed exclusive rights to develop, manufacture, and commercialize OC-3, a preclinical selective PARP1...
Independent research teams validate Apeximmune's PLA2G2D target for overcoming anti-PD-1 resistance
A Nature publication has given South San Francisco-based Apeximmune Therapeutics substantial external validation, with two independent research teams...
Stanford spinout TwoStep raises USD 62.5m as lead peptide-drug conjugate clears FDA IND
San Carlos, California-based TwoStep Therapeutics has raised USD 62.5 million in an oversubscribed Series A financing round, coinciding with US FDA...
Alebund gains FDA IND clearance for IgA-cleaving AP308 in IgA nephropathy
Alebund Pharmaceuticals (HKEX: 09637) received US FDA clearance of its investigational new drug (IND) application for AP308, an engineered recombinant IgA...
IDEAYA, Servier expand darovasertib into Phase III adjuvant uveal melanoma
San Francisco-based IDEAYA Biosciences (Nasdaq: IDYA) and France-based Servier announced that the first patient has been dosed in OptimUM-11, a global Phase...
InnoCare gains China IND clearance for PSMA/STEAP1 bispecific ADC ICP-B381
China's drug regulator has cleared InnoCare Pharma (HKSE: 9969) to begin clinical testing of ICP-B381, a bispecific antibody-drug conjugate (ADC) designed...
Kura launches Caspian with USD 50m to advance menin inhibition in diabetes
A USD 50 million financing round has backed the launch of Caspian Therapeutics, a newly formed company spun out of San Diego-based Kura Oncology (Nasdaq:...
UC Davis researchers map LSD structure to guide non-hallucinogenic drug design
Researchers at the University of California, Davis have used systematic chemical deconstruction of lysergic acid diethylamide (LSD) to identify which...
Harbour Bio partner Solstice raises USD 225m to advance CTLA-4 antibody in neoadjuvant cancer
Boston-based Solstice Oncology launched with a USD 225 million Series A financing to advance porustobart (HBM4003), an Fc-enhanced CTLA-4 antibody that...
Leyden Labs advances RIG-101 after Phase I shows safety and on-target immune activation
Phase I data from Netherlands-based Leyden Laboratories B.V.'s intranasal innate immune modulator RIG-101 showed acceptable safety and on-target...
Prana reports prolonged Type 2 biomarker suppression with IL-4Rα/TSLP bispecific
Phase I data from a placebo-controlled study in healthy adults suggest that PRA-216, a bispecific antibody that simultaneously blocks IL-4Rα and TSLP, can...
Lancet data show durable responses with PeproMene's BAFF-R CAR T after CD19 CAR T failure
Phase I data for PMB-CT01, a B-cell activating factor receptor (BAFF-R)-targeted autologous chimeric antigen receptor (CAR) T-cell therapy, have been...
Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy
Pharvaris N.V. (Nasdaq: PHVS) has reported an 83% reduction in monthly hereditary angioedema (HAE) attack rate with deucrictibant extended-release (XR)...
Schrödinger spins out Tectora with USD 55m Series A for immunology programs
Schrödinger (Nasdaq: SDGR) has licensed two early-stage small molecule immunology and inflammation programs to Tectora Therapeutics, a newly formed...
Assembly Bio converts HSV program from royalty deal to 40% US profit-share with Gilead
Assembly Biosciences (Nasdaq: ASMB) has exercised its embedded option to co-share 40% of US development costs and profits for the herpes simplex virus (HSV)...
The AllSci Brief
Free, systematic R&D and deal news. Daily.